Translate Bio Stock Price - TBIO

19.7936
0.0536 (0.27%)
19.74
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Translate Bio Inc TBIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.98 -4.73% 19.74 19.3101 20.60 20.56 20.72 16:08:56
Bid Price Ask Price Spread Spread % News
19.60 19.80 0.20 1.01% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,328 454,924 $ 19.90 $ 9,051,156 816,772 6.80 - 21.95
Last Trade Time Type Quantity Stock Price Currency
16:09:04 formt 150 $ 19.7936 USD

Translate Bio Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.24B 62.91M 61.86M $ 7.80M $ - -2.23 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 5.00 1.70%

more financials information »

Translate Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TBIO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week20.8721.7516.500120.19715,350-1.13-5.41%
1 Month13.2521.9512.8117.54754,0286.4948.98%
3 Months6.9821.956.8013.43654,48612.76182.81%
6 Months10.1021.956.8011.86439,1079.6495.45%
1 Year10.4021.956.8011.03345,8369.3489.81%
3 Years11.5021.954.8110.63252,9638.2471.65%
5 Years2.6321.950.1513.86440,56517.11650.57%

Translate Bio Description

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.